Jane Street Group, LLC Tcr2 Therapeutics Inc. Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.83 - $1.44 $21,208 - $36,796	25,553 Added 162.32%	41,295 $41,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $4,726 - $9,528	2,541 Added 19.25%	15,742 $28,000
Q2 2022 Aug 16, 2022	BUY	$2.11 - $2.94 $27,854 - $38,810	13,201 New	13,201 $38,000
Q1 2022 May 17, 2022	SELL	$2.4 - $4.71 $151,540 - $297,398	-63,142 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$4.58 - $8.34 $237,926 - $433,254	51,949 Added 464.12%	63,142 $294,000
Q3 2021 Nov 16, 2021	SELL	$8.44 - $18.35 $301,704 - $655,957	-35,747 Reduced 76.15%	11,193 $95,000
Q1 2021 May 18, 2021	BUY	$20.38 - $34.07 $459,813 - $768,687	22,562 Added 92.55%	46,940 $1.04 Million
Q4 2020 Feb 17, 2021	BUY	$19.0 - $32.63 $463,182 - $795,454	24,378 New	24,378 $754,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.